Q301--Minimal Residual Disease (MRD)/Testing Services

Sources Sought Notice: National Precision Oncology Program: Minimal Residual Disease (MRD)/Testing Services

THIS IS A REQUEST FOR INFORMATION (RFI) ONLY. This Sources Sought Notice is issued solely for information and planning purposes it does not constitute a Request for Proposal (RFP) or a promise to issue an RFP in the future. This notice does not commit the Government to contract for any supplies/or services whatsoever. Furthermore, the Government is not at this time seeking proposals and will not accept unsolicited offers. Interested vendors are advised that the Government will not pay for any information or administrative costs incurred in the response to this Notice. All costs associated with responding to this notice will be solely at the interested party s expense. Not responding to this notice does not preclude participation in any future RFP, if issued. If a solicitation is released, it will be synopsized on https://www.sam.gov. It is the responsibility of the potential offerors to monitor this site for additional information pertaining to this requirement.

The Department of Veterans Affairs (VA), National Oncology Program office is conducting market research to identify potential contractors that may possess the expertise, capabilities, and experience for the acquisition of specialized, comprehensive reference laboratory services from contractor(s) with the capability and expertise to provide molecular testing for Minimal Residual Disease (MRD) testing for patients diagnosed with colon cancer. Colon cancer is One of the top 3 cancers diagnosed in Veterans. MRD testing in stage II colorectal cancers post resection has been shown to help guide management decisions regarding the need for adjuvant chemotherapy.

There are different methods that are used to detect MRD, including:

Next generation genetic sequencing:Â Analyzes bone marrow samples for genetic mutations.Â

Flow cytometry:Â Looks for abnormal proteins on the surface of cells.Â

Polymerase chain reaction (PCR):Â Amplifies small amounts of DNA to make it easier to detect and count.Â

The choice of method depends on the type of cancer and its molecular signatures.

Contractor(s) that respond to this RFI must provide specifically demonstrated history of molecular testing of samples from patients in New York State and is preferably certified through Clinical Laboratory Improvement Amendments (CLIA) to service all 50 states to include, the District of Columbia, and Puerto Rico.

The North American Industry Classification System Code (NAICS) Code for this requirement is 621511, Medical Laboratories. The information that is received from this notice will be used to make the best decision on how to proceed with this acquisition. Information received will not be shared with other potential offerors. If your firm is interested in this RFI and can provide the testing service as stated, please respond to this post to Michelle Bailey, at michelle.bailey@va.gov and Zachary Wilcox, Zachary.wilcox@va.gov. The closing date of this RFI will be February 13, 2025, 2pm EST. All responses will need to be submitted by the closing to the provided contracting staff.

Requested Information

Company Name:

Point of Contact Information:

Name:

Email:

Phone Number:

Cage Code:

Company Socio-Economic Status (i.e. Woman Owned, Veteran Owned, Disabled Veteran Owned, etc):

Company Business Size for NAICS Code:

Does your MRD testing have published, peer-reviewed data supporting the validity of the test? If yes, please provide the publication reference.

Is your MRD Testing considered to be experimental in nature?

Please provide a copy of your capabilities statement for your company when replying to this posting.